FibroGen appoints Thane Wettig as Interim CEO; Enrique Conterno resigns

KYNTRA BIO, INC.

Thane Wettig, previously Chief Commercial Officer, named Interim CEO effective July 23, 2023.
Enrique Conterno resigned as CEO and from the Board; will serve as Special Advisor through August 8, 2023.
Conterno's resignation not due to any disagreement with the company.
Wettig receives monthly $10,000 stipend on $545,000 base salary; bonus target rises to 75% of base as Interim CEO.
Conterno entered consulting agreement at $35,000 per month through September 30, 2023.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Enrique Conterno

Chief Executive Officer

KYNB · KYNTRA BIO, INC.

Effective: 2023-07-23
Successor: Thane Wettig
Filed: July 25, 2023, 7:59 PM ET

He succeeds Enrique Conterno, who has resigned as Chief Executive Officer and from the Board, and who will remain with the Company as Special Advisor to the Interim CEO through August 8, 2023.

Appointed (interim)

Thane Wettig

Interim Chief Executive Officer

KYNB · KYNTRA BIO, INC.

Effective: 2023-07-23
Filed: July 25, 2023, 7:59 PM ET

the Board of Directors (the "Board") has appointed Thane Wettig, age 58, to the position of Interim Chief Executive Officer (“Interim CEO”), effective July 23, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Enrique Conterno resigned as Chief Executive Officer at KYNTRA BIO, INC..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

He succeeds Enrique Conterno, who has resigned as Chief Executive Officer and from the Board, and who will remain with the Company as Special Advisor to the Interim CEO through August 8, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Thane Wettig was appointed as Interim Chief Executive Officer at KYNTRA BIO, INC..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

the Board of Directors (the "Board") has appointed Thane Wettig, age 58, to the position of Interim Chief Executive Officer (“Interim CEO”), effective July 23, 2023.

View on SEC.gov

KYNTRA BIO, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-034234

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.